Relay Therapeutics (RLAY) Free Cash Flow (2019 - 2026)
Relay Therapeutics (RLAY) reported Free Cash Flow of -$51.1 million for Q1 2026, up 30.55% year-over-year from -$39.2 million in Q1 2025, and down 13.92% quarter-over-quarter from -$44.9 million in Q4 2025.
Relay Therapeutics (RLAY) Free Cash Flow (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has 8 years of Free Cash Flow data on file, last reported at -$51.1 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$51.1 million, up 30.55% year-over-year; the trailing twelve-month figure through Mar 2026 was -$213.4 million (up 21.73% YoY), and the FY2025 annual result was -$235.9 million, up 6.08% from the prior year.
- Free Cash Flow fell to -$51.1 million in Q1 2026 per RLAY's latest filing, from -$44.9 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$44.9 million in Q4 2025 and troughed at -$89.3 million in Q4 2023.
- A 5-year average of -$63.6 million and a median of -$62.1 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow tumbled 211.66% in 2022, then soared 35.2% in 2024.
- A 5-year view of Free Cash Flow shows it stood at -$59.4 million in 2022, then slumped by 50.36% to -$89.3 million in 2023, then soared by 35.2% to -$57.9 million in 2024, then gained by 22.47% to -$44.9 million in 2025, then fell by 13.92% to -$51.1 million in 2026.
- Business Quant data shows RLAY's Free Cash Flow at -$51.1 million in Q1 2026, -$44.9 million in Q4 2025, and -$62.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 63,220.27 |
| 10 | Relay Therapeutics | 2.86 Bn | 2.86 Bn | - | -51.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -51.11 Mn |
| Mar 31, 2026 | -51.11 Mn |
| Dec 31, 2025 | -44.87 Mn |
| Dec 31, 2025 | -44.87 Mn |
| Sep 30, 2025 | -62.12 Mn |
| Sep 30, 2025 | -62.12 Mn |
| Jun 30, 2025 | -55.29 Mn |
| Jun 30, 2025 | -55.29 Mn |
| Mar 31, 2025 | -73.59 Mn |
| Mar 31, 2025 | -73.59 Mn |
| Dec 31, 2024 | -57.87 Mn |
| Dec 31, 2024 | -57.87 Mn |
| Sep 30, 2024 | -75.31 Mn |
| Sep 30, 2024 | -75.31 Mn |
| Jun 30, 2024 | -65.84 Mn |
| Jun 30, 2024 | -65.84 Mn |
| Mar 31, 2024 | -52.10 Mn |
| Mar 31, 2024 | -52.10 Mn |
| Dec 31, 2023 | -89.31 Mn |
| Dec 31, 2023 | -89.31 Mn |